HR 465 · 116th Congress 2019โ€“2021, ended

Prescription Drug Price Relief Act of 2019

Latest action · Jan 25, 2019 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJan 10, 2019
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Prescription Drug Price Relief Act of 2019

This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Cosponsors 22

Members who signed on, in the order they did. Signatures ran from Jan 10, 2019 to Apr 30, 2019; 14 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-NYAlexandria Ocasio-CortezOriginalJan 10, 2019
D-MAAyanna PressleyOriginalJan 10, 2019
D-CABarbara LeeOriginalJan 10, 2019
D-MDElijah E. CummingsOriginalJan 10, 2019
D-MNIlhan OmarOriginalJan 10, 2019
D-ILJanice D. SchakowskyOriginalJan 10, 2019
D-COJoe NeguseOriginalJan 10, 2019
D-WIMark PocanOriginalJan 10, 2019
D-ORPeter A. DeFazioOriginalJan 10, 2019
D-VTPeter WelchOriginalJan 10, 2019
D-WAPramila JayapalOriginalJan 10, 2019
D-MIRashida TlaibOriginalJan 10, 2019
D-CTRosa L. DeLauroOriginalJan 10, 2019
D-HITulsi GabbardOriginalJan 10, 2019
D-FLDebbie Mucarsel-PowellJan 15, 2019
D-NMDebra A. HaalandJan 15, 2019
D-DCEleanor Holmes NortonJan 15, 2019
D-CAMark DeSaulnierJan 15, 2019
D-ILDanny K. DavisJan 22, 2019
D-MDJamie RaskinJan 28, 2019
D-CALucille Roybal-AllardFeb 5, 2019
D-NYGrace MengApr 30, 2019

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jan 10, 2019
Health Subcommittee
Referred Jan 25, 2019
HouseJudiciary Committee
Referred Jan 10, 2019
Administrative State, Regulatory Reform, and Antitrust Subcommittee
Referred Jan 10, 2019

Actions 4

Everything that happened, newest first.

  1. Jan 25, 2019Referred to the Subcommittee on Health.
  2. Jan 10, 2019Introduced in House
  3. Jan 10, 2019Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Jan 10, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section VIII, of the United States Constitution

The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 5, January 10, 2019, page H464.

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

Related bills 2

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 102Prescription Drug Price Relief Act of 2019Identical billJan 10, 2019
HR 2148Prescription Drug Price Relief Act of 2021Reintroduced BillOct 19, 2021

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
Short Title(s) as Introduced
Prescription Drug Price Relief Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Jan 10, 2019Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.